NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
43598-0515-21 | 43598-0515 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
60505-4534-02 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
47781-0486-77 | 47781-0486 | Lenalidomide | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 3, 2022 | In Use | |
59572-0504-00 | 59572-0504 | Pomalidomide | Pomalyst | 4.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
69448-0015-05 | 69448-0015 | Trastuzumab-strf | HERCESSI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
00085-1110-01 | 00085-1110 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Jul 31, 2016 | No Longer Used | ||
00085-1287-03 | 00085-1287 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
55513-0059-01 | 55513-0059 | Tarlatamab-dlle | IMDELLTRA (AMG757) | 1.0 mg/1 | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | Intravenous | May 16, 2024 | In Use | |
00115-1476-23 | 00115-1476 | Imiquimod | Imiquimod | 50.0 mg/g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Feb 28, 2011 | Jun 1, 2017 | No Longer Used |
00024-0654-01 | 00024-0654 | Isatuximab | Sarclisa | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Mar 2, 2020 | In Use | |
61755-0008-01 | 61755-0008 | cemiplimab-rwlc | LIBTAYO | 50.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 28, 2018 | In Use | |
50242-0070-01 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 1, 2013 | In Use | |
00469-4425-30 | 00469-4425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Apr 24, 2025 | In Use | |
43598-0516-63 | 43598-0516 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
63304-0045-22 | 63304-0045 | Lenalidomide | Lenalidomide | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 12, 2023 | In Use | |
52658-7777-01 | 52658-7777 | Denileukin diftitox-cxdl | LYMPHIR | 300.0 ug/2mL | Immunotherapy | Cytokine | Interleukin-2 | Intravenous | Mar 1, 2025 | In Use | |
00078-0690-61 | 00078-0690 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | In Use | |
31722-0260-01 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
63459-0303-43 | 63459-0303 | TRASTUZUMAB | HERZUMA | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Mar 16, 2020 | In Use | |
00480-1244-21 | 00480-1244 | Lenalidomide | Lenalidomide | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2022 | In Use | |
31722-0260-21 | 31722-0260 | LENALIDOMIDE | LENALIDOMIDE | 15.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | May 11, 2023 | In Use | |
63304-0042-01 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
83444-0301-10 | 83444-0301 | Cosibelimab | UNLOXCYT | 300.0 mg/5mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Jun 30, 2025 | In Use | |
00008-0100-01 | 00008-0100 | Inotuzumab Ozogamicin | Besponsa | 0.25 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | Aug 18, 2017 | In Use |
Found 11765 results — Export these results